NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that it will host a Key Opinion Leader (KOL) webinar, entitled: “Presbyopia in Focus: Unlocking one of the Biggest Market Opportunities in Ophthalmology,” on Monday, February 22, 2021 at 1:00pm Eastern Time.
The event will feature a fireside chat with KOL David F. Chang, M.D., past-president of the American Society of Cataract and Refractive Surgery (ASCRS), and Sean Ianchulev, M.D. M.P.H., Chief Executive Officer of Eyenovia and Professor of Ophthalmology, who will discuss various topics related to presbyopia and the potential benefits of treating patients with Eyenovia's MicroLine formulation technology.
Presbyopia is a non-preventable, age-related hardening of the lens, which causes the gradual loss of the eye’s ability to focus on nearby objects, commonly known as farsightedness. There are currently no known FDA-approved drugs for the improvement in near vision in patients with presbyopia and existing modalities are typically device-based, such as reading glasses or contact lenses. In the United States, presbyopia affects an estimated 113 million people, with about 40% between the ages of 40 and 60 who have otherwise normal vision that Eyenovia predicts could most benefit from a pharmacologic treatment option like MicroLine.
Eyenovia is currently evaluating MicroLine, its pilocarpine formulation administered via its proprietary Optejet microdose dispenser, in two Phase 3 studies, VISION-1 and VISION-2. Topline results from VISION-1 are anticipated in the first half of 2021.
A Q&A session will follow the formal presentations.
To register for the webinar, please click here.
A graduate of Harvard College and Harvard Medical School, David F. Chang, M.D. is a clinical professor at the University of California, San Francisco. He previously chaired the ASCRS Cataract Clinical Committee and is on the ASCRS executive committee, serving as president in 2012-2013. Dr. Chang is also Chairman of the AAO Cataract Preferred Practice Pattern Committee, immediate past chair of the AAO Practicing Ophthalmologist Curriculum Panel for Cataract/Anterior Segment, and in 2009 completed his 5-year term as chair of the AAO Annual Meeting program committee. He is the chief medical editor of EyeWorld and was previously co-chief medical editor for Cataract and Refractive Surgery Today.
Dr. Chang has received the highest honor for cataract surgery from ASCRS (Binkhorst Medal), the AAO (Kelman Lecture), the Asia Pacific Association of Cataract & Refractive Surgery (Lim Medal), the United Kingdom and Ireland Society of Cataract & Refractive Surgery (Rayner Medal), the Canadian Society of Cataract and Refractive Surgery (Stein Lecture/Award of Excellence), the Indian Intraocular Implant & Refractive Society (Gold Medal), the Italian Ophthalmological Society (Strampelli Medal), the Royal Australia and New Zealand College of Ophthalmologists (Gregg Medal), and the Asia Pacific Academy of Ophthalmology (Keynote Lecture). In 2006, he became only the third ophthalmologist to ever receive the Charlotte Baer Award honoring the outstanding clinical faculty member at the UCSF Medical School.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia recently submitted a US FDA NDA for MydCombi™, its product candidate for mydriasis. In addition to MicroLine for presbyopia, the Company is in late-state development of a microdosed medication for myopia progression. For more Information, please visit www.eyenovia.com.
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing and our ability to submit applications for, obtain and maintain regulatory approvals for our product candidates; our estimates regarding potential market opportunities in ophthalmology and for our product candidates; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Chief Financial Officer
Eyenovia Investor Contact:
LifeSci Advisors, LLC
Eyenovia Media Contact:
Pazanga Health Communications